Your browser is no longer supported. Please, upgrade your browser.
NXTC NextCure, Inc. daily Stock Chart
NextCure, Inc.
Index- P/E- EPS (ttm)-1.92 Insider Own3.50% Shs Outstand22.02M Perf Week15.84%
Market Cap656.86M Forward P/E- EPS next Y-2.03 Insider Trans- Shs Float20.15M Perf Month55.20%
Income- PEG- EPS next Q-0.48 Inst Own47.80% Short Float0.46% Perf Quarter52.43%
Sales2.76M P/S238.08 EPS this Y-47.40% Inst Trans- Short Ratio1.34 Perf Half Y-
Book/sh7.86 P/B3.80 EPS next Y6.10% ROA- Target Price28.67 Perf Year-
Cash/sh8.75 P/C3.41 EPS next 5Y28.50% ROE- 52W Range13.86 - 29.87 Perf YTD49.90%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-0.13% Beta-
Dividend %- Quick Ratio17.10 Sales past 5Y- Gross Margin- 52W Low115.22% ATR2.05
Employees44 Current Ratio17.10 Sales Q/Q- Oper. Margin- RSI (14)75.06 Volatility9.61% 8.62%
OptionableNo Debt/Eq0.03 EPS Q/Q- Profit Margin- Rel Volume0.58 Prev Close29.52
ShortableYes LT Debt/Eq0.02 EarningsSep 09 Payout- Avg Volume69.85K Price29.83
Recom1.70 SMA2026.02% SMA5055.06% SMA20056.48% Volume40,683 Change1.05%
Jul-09-19Initiated BofA/Merrill Buy $25
Jun-03-19Initiated Piper Jaffray Overweight $26
Jun-03-19Initiated Morgan Stanley Overweight $25
Aug-12-19 04:05PM  NextCure Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-08-19 06:02AM  What Kind Of Shareholder Owns Most NextCure, Inc. (NASDAQ:NXTC) Stock? Simply Wall St. -6.68%
Jul-18-19 11:20AM  2 Small-Cap Biotech IPOs You Should Know About Motley Fool +6.36%
Jun-10-19 04:05PM  NextCure Reports First Quarter 2019 Financial Results GlobeNewswire -5.67%
May-08-19 08:46PM  NextCure Announces Pricing of Initial Public Offering of Common Stock GlobeNewswire
May-04-19 05:25PM  IPO Outlook For The Week: Uber (And 11 Others) Benzinga
NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.